François-Xavier D.
- Country
- France
- Department
- DITEP
Research Overview
- Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of PTT-4256 Monotherapy or in Combination with Nivolumab in Patients with Solid Tumours
- Phase 1/2 Study of RPTR-1-201 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
- An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies
Data & Insights
Has run more than one trial at 5 of 15 partner sites.
Specializations
Hematologic Malignancies
The investigator is involved in clinical research on acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and other relapsed or refractory blood cancers, with an interest in treatment-resistant disease and molecularly defined subgroups.
- Acute leukemia
- Myelodysplastic syndrome
- Diffuse large B-cell lymphoma
- Multiple myeloma
Research activity also extends to lymphoma variants, chronic lymphocytic leukemia, and graft-versus-host disease, reflecting a strong focus on advanced hematology and cellular therapy-related care.
Thoracic and Lung Cancer
Clinical trials under this investigator include a broad range of non-small cell lung cancer and small cell lung cancer settings, including biomarker-selected disease and advanced thoracic malignancies.
- Non-small cell lung cancer
- Small cell lung cancer
- Mesothelioma
- Head and neck squamous cell carcinoma
Interest also covers EGFR-altered, ALK-positive, ROS1-positive, and HER2-altered lung cancers, alongside other thoracic tumors requiring targeted and immunologic strategies.
Breast and Gynecologic Oncology
The investigator is active in studies of breast cancer, including HER2-positive, HER2-low, triple-negative breast cancer, and hormone receptor-positive disease, as well as ovarian cancer and endometrial cancer.
- Triple-negative breast cancer
- Ovarian cancer
- Endometrial cancer
- Cervical cancer
Research also includes fallopian tube cancer, primary peritoneal cancer, and biomarker-driven treatment approaches in advanced gynecologic malignancies.
Gastrointestinal and Hepatobiliary Cancers
Clinical research involvement spans colorectal cancer, gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and biliary tract cancer, with attention to both localized and metastatic disease.
- Colorectal cancer
- Pancreatic ductal adenocarcinoma
- Gastric cancer
- Hepatocellular carcinoma
The portfolio also includes esophageal cancer, gastrointestinal stromal tumor, and neuroendocrine tumors across digestive and hepatobiliary oncology.
Genitourinary, Sarcoma, and Molecularly Selected Solid Tumors
The investigator is engaged in trials for prostate cancer, renal cell carcinoma, and urothelial carcinoma, alongside sarcoma and other advanced solid tumors defined by actionable alterations.
- Prostate cancer
- Renal cell carcinoma
- Urothelial carcinoma
- Soft tissue sarcoma
Additional interests include melanoma, glioblastoma, molecularly targeted solid tumors, and rare cancers with specific genomic alterations such as KRAS, FGFR, RET, and MTAP changes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.